Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc. (BLPH) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
blph · stock forecast · 8 analysts (3M) · FMP · updated Apr 22, 2025
Analyst Rating & Consensus
Based on 8 Wall Street analysts in the past 3 months
Buy
8 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.01
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.01 | ↑ 0.00% |
1-day model range: $0.01–$0.01. Peak: $0.01 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · BLPH · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-06-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-06-06 | Laidlaw & Co. | Downgrade ↓ | Buy→Hold |
| 2023-06-05 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-06-05 | Laidlaw & Co. | Downgrade ↓ | Buy→Hold |
| 2023-05-09 | Laidlaw & Co. | Maintains | Buy→Buy |
| 2023-04-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2020-11-25 | Maxim Group | Maintains | Buy→Buy |
| 2020-11-25 | Leerink Swann | Maintains | Outperform→Outperform |
| 2020-11-25 | Jefferies | Maintains | Buy→Buy |
| 2020-11-25 | H.C. Wainwright | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Bellerophon Therapeutics, Inc. (BLPH) stock. Of the recent 17 rating actions, 0 were upgrades and 2 were downgrades. 8 analysts currently cover BLPH.
Analyst Recommendation Trends
BLPH analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$6M
↓ 93.6% YoY
Revenue Next Year
$28M
↑ 395.9% YoY
EPS This Year
$-1.51
EPS Next Year
$-1.02
↓ 32.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast BLPH EPS of $-1.51 for the current fiscal year, based on estimates from 1 analysts. The BLPH revenue forecast is $6M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BLPH stock forecast is supported by two independent data sources: analyst consensus ratings from 8 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BLPH price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The BLPH short-term stock prediction for tomorrow is $0.01 (+0.00%).
Bellerophon Therapeutics, Inc. trades on NASDAQ under the ticker BLPH. The BLPH stock outlook for 2027 is broadly positive, supported by a Buy consensus among 88% of covering analysts.
Frequently asked questions
BLPH forecast · 8 questionsAccording to 8 Wall Street analysts, the average 12-month BLPH price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.